To Live or to Die: Prosurvival Activity of PPAR𝜸 in Cancers

Table 7

Clinical trials of TZDs in cancer patients.

Cancer type	Phase	TZDs	No. of pts	Tumor response	References
Liposarcoma	II	Rosiglitazone	12	All patients progressed, no sign of differentiation by histology	[68]
Thyroid cancer	I, II	Rosiglitazone	10	4 pts with partial response, 2 with stable disease, and 4 with progressed disease	[69]
Metastatic colorectal cancer	I, II	Troglitazone	25	All patients progressed	[70]
Refractory breast cancer	II	Troglitazone	22	Most patients progressed with increased serum tumor markers	[71]
Early-stage breast cancer	II	Rosiglitazone	38	No reduction in Ki-67 staining on tissue biopsies	[72]
Metastatic prostate cancer	II	Troglitazone	41	Decrease or stabilization of PSA	[73]
Recurrent prostate cancer	III	Rosiglitazone	106	Similar to placebo in both PSADT and time-to-disease-progression	[74]